2kd3

Publication Abstract from PubMed

Sclerostin has been identified as a negative regulator of bone growth. Initially it was considered that Sclerostin performs its regulatory function via acting as a modulator of bone morphogenetic proteins (BMPs) similar to known examples such as Noggin, Chordin, and members of the DAN family. Recent findings, however, show that Sclerostin interferes with the Wnt signaling pathway due to binding to the Wnt co-receptor LRP5 thereby modulating bone growth. As Sclerostin is exclusively produced by osteocytes located in bones, neutralization of its bone-inhibiting functions makes it a highly interesting target for an osteoanabolic therapeutic approach in diseases characterized by bone loss, such as osteoporosis. Despite the huge interest in Sclerostin inhibitors the molecular basis of its function and its interaction with components of the Wnt signaling cascade has remained unclear. Here, we present the NMR structure of murine Sclerostin providing the first insights how Sclerostin might bind to LRP5.

NMR structure of the Wnt modulator protein Sclerostin.,Weidauer SE, Schmieder P, Beerbaum M, Schmitz W, Oschkinat H, Mueller TD Biochem Biophys Res Commun. 2009 Feb 27;380(1):160-5. Epub 2009 Jan 21. PMID:19166819^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.